許偉帆 Wei-Fan Hsu 主治醫師
許偉帆醫師的專長在各種腹部超音波檢查、消化道內視鏡、大腸鏡檢查，幫助各種消化系統疾病的診療。內視鏡配合麻醉檢查，可以避免檢查時之疼痛不適。臨床擅長領域包含：肝炎、脂肪肝、肝硬化及其相關併發症、與一般腸胃疾病等；近來脂肪肝越來越受重視，許醫師在此有所專研。許偉帆醫師兼具中醫師執照，對於內科與消化系疾病有中醫需求的民眾請預約許醫師週一夜診時段。
學術機構典藏
論文
期刊論文
|
期刊論文／Journal Paper (作者群，論文題目，期刊名稱，出版年月，卷號(期別):頁次起迄) |
日期 | |
| 1 | 許偉帆(Hsu, Wei-Fan)、李旻憲(Ming-Hsien Lee)、李宗貴(Chong-Kuei Lii)*、彭成元(Peng, Cheng-Yuan)*，No Difference in Liver Damage Induced by Isocaloric Fructose or Glucose in Mice with a High-Fat Diet，Nutrients，2024 Oct，16(20):3571 | 2024 . 10 |
| 2 | (Meng Wu)*、(Claudia AM Fulgenzi)、(Antonio D’Alessio)、(Alessio Cortellini)、(Ciro Celsa)、(Giulia F Manfredi)、(Bernardo Stefanini)、(Y. Linda Wu)、黃怡翔(Yi-Hsiang Huang)、(Anwaar Saeed)、許偉帆(Hsu, Wei-Fan)，Second-line Treatment Patterns and Outcomes in Advanced HCC after Progression on Atezolizumab/Bevacizumab，JHEP Reports，2024 Oct，6(): | 2024 . 10 |
| 3 | (Claudia Angela Maria Fulgenzi)、(Bernhard Scheiner)、(Antonio D’Alessio)、(Aman Mehan)、(Giulia F. Manfredi)、(Ciro Celsa)、(Naoshi Nishida)、(Celina Ang)、(Thomas U. Marron)、(Linda Wu)、許偉帆(Hsu, Wei-Fan)、(David James Pinato)*，Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction，JAMA Oncology，2024 Sep，10(9):1253-1258 | 2024 . 09 |
| 4 | 王鴻偉(Hung-Wei Wang)、賴學洲(Hsueh-Chou Lai)*、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao)、許偉帆(Hsu, Wei-Fan)、陳浤燿(Hung-Yao Chen)、張哲維(Che-Wei Chang)、黃冠棠(Guan-Tarn Huang)、彭成元(Peng, Cheng-Yuan)*，Real-world experience of lenvatinib-based therapy in patients with advanced hepatocellular carcinoma，Journal of Gastrointestinal Oncology，2024 Sep，0(0):0-0 | 2024 . 09 |
| 5 | 張維(Chang Chin Wei)、許偉帆(Hsu, Wei-Fan)、曾國枝(Kuo-Chih Tseng)、陳啟益(Chi-Yi Chen)、鄭斌男(Pin-Nan Cheng)、洪肇宏(Chao?Hung Hung)、羅清池(Ching-Chu Lo)、白明忠(Ming-Jong Bair)、陳建宏(Chien-Hung Chen)、李佩倫(Pei-Lun Lee)、林俊彥(Chun-Yen Lin)、郭行道(Hsing-Tao Kuo)、蘇維文(Wei-Wen Su)、蔡維倫(Wei-Lun Tsai)、黃怡翔(Yi-Hsiang Huang)、鄭健禹(Chien-Yu Cheng)、林志陵(Chih-Lin Lin)、王嘉齊(Chia-Chi Wang)、楊勝舜(Sheng-Shun Yang)、牟聯瑞(Lein-Ray Mo)、陳桂英(Guei-Ying Chen)、張君照(Chun-Chao Chang)、王嗣仁(Szu-Jen Wang)、黃嘉生(Chia?Sheng Huang)、謝財源(Tsai?Yuan Hsieh)、林志文(Chih?Wen Lin)、李宗熙(Tzong?Hsi Lee)、張麗文(Lee?Won Chong)、黃健維(Chien?Wei Huang)、張旭男(Shiuh?Nan Chang)、蔡明璋(Ming?Chang Tsai)、徐士哲(Shih?Jer Hsu)、高嘉宏(Jia?Horng Kao)、劉俊人(Chun?Jen Liu)、劉振驊(Chen?Hua Liu)、林漢傑(Han?Chieh Lin)、蔡佩倩(Pei?Chien Tsai)、葉明倫(Ming?Lun Yeh)、黃釧峰(Chung?Feng Huang)、戴嘉言(Chia?Yen Dai)、莊萬龍(Wan?Long Chuang)、余明隆(Ming Lung Yu)*、彭成元(Peng, Cheng-Yuan)*，Benefits of Hepatitis C Viral Eradication: A Real‑World Nationwide Cohort Study in Taiwan，DIGESTIVE DISEASES AND SCIENCES，2024 Jul，(): | 2024 . 07 |
| 6 | 陳昇弘(Chen, Sheng-Hung)、賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao)、許偉帆(Hsu, Wei-Fan)、王鴻偉(Hung-Wei Wang)、陳浤燿(Hung-Yao Chen)、彭成元(Peng, Cheng-Yuan)*，Liver stiffness and spleen stiffness predict distinct liver-related events after hepatitis C eradication with direct-acting antivirals，JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION，2024 Apr，S0929-6646(24):142-146 | 2024 . 04 |
| 7 | 許偉帆(Hsu, Wei-Fan)、賴學洲(Hsueh-Chou Lai)、陳昇弘(Chen, Sheng-Hung)、蘇文邦(Wen-Pang Su)、王鴻偉(Hung-Wei Wang)、陳浤燿(Hung-Yao Chen)、黃冠棠(Guan-Tarn Huang)、彭成元(Peng, Cheng-Yuan)*，Effect of metabolic dysfunction on the risk of liver-related events in patients cured of hepatitis C virus，American Journal of Cancer Research，2024 Apr，14(4):1914-1925 | 2024 . 04 |
| 8 | (Ciro Celsa)、(Giuseppe Cabibbo)、(Claudia AM Fulgenzi)、(Bernhard Scheiner)、(Antonio d’Alessio)、(Giulia F Manfredi)、(Naoshi Nishida)、(Celina Ang)、(Thomas U. Marron)、(Anwaar Saeed)、(Brooke Wietharn)、(Matthias Pinter)、(Jaekyung Cheon)、黃怡翔(Yi-Hsiang Huang)、李沛璋(Pei-Chang Lee)、(Samuel Phen)、(Anuhya Gampa)、(Anjana Pillai)、(Caterina Vivaldi)、(Francesca Salani)、(Gianluca Masi)、(Natascha Roehlen)、(Robert Thimme)、(Arndt Vogel)、(Martin Schonlein)、(Johann von Felden)、(Kornelius Schulze)、(Henning Wege)、(Peter R. Galle)、(Masatoshi Kudo)、(Lorenza Rimassa)、(Amit G. Singal)、(Paul El Tomb)、(Susanna Ulahannan)、(Alessandro Parisi)、(Hong Jae Chon)、許偉帆(Hsu, Wei-Fan)、(Bernardo Stefanini)、(Elena Verzoni)、(Raffaele Giusti)、(Antonello Veccia)、(Annamaria Catino)、(Giuseppe Aprile)、(Pamela Francesca Guglielmini)、(Marilena Di Napoli)、(Paola Ermacora)、(Lorenzo Antonuzzo)、(Ernesto Rossi)、(Francesco Verderame)、(Fable Zustovich)、(Corrado Ficorella)、(Francesca Romana Di Pietro)、(Nicola Battelli)、(Giorgia Negrini)、(Francesco Grossi)、(Roberto Bordonaro)、(Stefania Pipitone)、(Maria Banzi)、(Serena Ricciardi)、(Letizia Laera)、(Antonio Russo)、(Ugo De Giorgi)、(Luigi Cavanna)、(Mariella Soraru)、(Vincenzo Montesarchio)、(Paola Bordi)、(Leonardo Brunetti)、(Carmine Pinto)、(Melissa Bersanelli)、(Calogero Camma)、(Alessio Cortellini)、(David J Pinato)*，Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours，JOURNAL OF HEPATOLOGY，2024 Mar，80(3):431-442 | 2024 . 03 |
| 9 | 陳柏谷(PoKu Chen)、許偉帆(Hsu, Wei-Fan)、彭成元(Peng, Cheng-Yuan)、廖采苓(Tsai-Ling Liao)、張詩欣(Shih-Hsin Chang)、陳信華(Hsin-Hua Chen)、陳珠璜(Chu-Huang Chen)、陳得源(Der-Yuan Chen)*，Significant association of elevated serum galectin-9 levels with the development of non-alcoholic fatty liver disease in patients with rheumatoid arthritis，Frontiers in Medicine，2024 Feb，11():1347268 | 2024 . 02 |
| 10 | 張哲睿(CHANG CHE-JUI)、許偉帆(Hsu, Wei-Fan)*、鄭隆賓(Long-Bin Jeng)、賴學洲(Hsueh-Chou Lai)、許士超(Shih-Chao Hsu)、陳德鴻(Te-Hung Chen)、王鴻偉(Hung-Wei Wang)、彭成元(Peng, Cheng-Yuan)，Adjuvant Sorafenib for Postoperative Patients with Hepatocellular Carcinoma and Macrovascular Invasion，Current Oncology，2023 Nov，30(12):10134-10141 | 2023 . 11 |
| 11 | 許偉帆(Hsu, Wei-Fan)、賴學洲(Hsueh-Chou Lai)、陳政國(Cheng-Kuo Chen)、王鴻偉(Hung-Wei Wang)、莊伯恒(Po-Heng Chuang)、蔡明宏(Ming-Hung Tsai)、陳昇弘(Chen, Sheng-Hung)、朱家聲(Chia-Sheng Chu)、蘇文邦(Wen-Pang Su)、周仁偉(Jen-Wei Chou)、高榮達(Jung-Ta Kao)、陳浤燿(Hung-Yao Chen)、莊世杰(Shih-Chieh Chuang)、蔡宗佑(Tsung-Yu Tsai)、蕭望德(Won-Der Shau)、黃冠棠(Guan-Tarn Huang)、彭成元(Peng, Cheng-Yuan)*，Combined CRAFITY score and α-fetoprotein response predicts treatment outcomes in patients with unresectable hepatocellular carcinoma receiving anti-programmed death-1 blockade-based immunotherapy，American Journal of Cancer Research，2023 Feb，13(2):654-668 | 2023 . 02 |
| 12 | 許偉帆(Hsu, Wei-Fan)、許士超(Shih-Chao Hsu)、陳德鴻(Te-Hung Chen)、林建宏(Chien-Hung Lin)、林膺峻(Lin,Ying-Chun)、張裕煒(Yu-Wei Chang)、王鴻偉(Hung-Wei Wang)、廖裕民(Yu-Min Liao)、賴學洲(Hsueh-Chou Lai)、彭成元(Peng, Cheng-Yuan)*，Modified Albumin–Bilirubin Model for Stratifying Survival in Patients with Hepatocellular Carcinoma Receiving Anticancer Therapy，Cancers，2022 Oct，14(20):5083 | 2022 . 10 |
| 13 | 陳昇弘(Chen, Sheng-Hung)、賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao)、莊伯恒(Po-Heng Chuang)、許偉帆(Hsu, Wei-Fan)、王鴻偉(Hung-Wei Wang)、謝宗霖(Tsung-Lin, Hsieh)、陳浤燿(Hung-Yao Chen)、彭成元(Peng, Cheng-Yuan)*，Combined Liver Stiffness and Α-fetoprotein further beyond the Sustained Virologic Response Visit as Predictors of Long-term Liver-related Events in Patients With Chronic Hepatitis C，Canadian Journal of Gastroenterology and Hepatology，2022 Jul，2022():5201443-5201443 | 2022 . 07 |
| 14 | 許偉帆(Hsu, Wei-Fan)、賴學洲(Hsueh-Chou Lai)、莊伯恒(Po-Heng Chuang)、蘇文邦(Wen-Pang Su)、陳昇弘(Chen, Sheng-Hung)、陳浤燿(Hung-Yao Chen)、王鴻偉(Hung-Wei Wang)、黃冠棠(Guan-Tarn Huang)、彭成元(Peng, Cheng-Yuan)*，Posttreatment nonalcoholic fatty liver disease fibrosis scores for predicting liver-related complications in patients with chronic hepatitis C receiving direct-acting antiviral agents，JOURNAL OF VIRAL HEPATITIS，2022 Jun，29():01-10 | 2022 . 06 |
| 15 | 陳昇弘(Chen, Sheng-Hung)、賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao)、莊伯恒(Po-Heng Chuang)、許偉帆(Hsu, Wei-Fan)、王鴻偉(Hung-Wei Wang)、蔡宗佑(Tsung-Yu Tsai)、陳浤燿(Hung-Yao Chen)、彭成元(Cheng-Yuan Peng)*，Liver and spleen stiffness surveillance through elastography during and after direct-acting antiviral therapy in patients with chronic hepatitis C，JOURNAL OF ULTRASOUND IN MEDICINE，2022 Apr，41(5):1169-1177 | 2022 . 04 |
| 16 | 許偉帆(Hsu, Wei-Fan)、王鴻偉(Hung-Wei Wang)、陳政國(Cheng-Kuo Chen)、賴學洲(Hsueh-Chou Lai)、莊伯恒(Po-Heng Chuang)、蔡明宏(Ming-Hung Tsai)、蘇文邦(Wen-Pang Su)、陳浤燿(Hung-Yao Chen)、朱家聲(Chia-Sheng Chu)、周仁偉(Jen-Wei Chou)、陳昇弘(Chen, Sheng-Hung)、蔡宗佑(Tsung-Yu Tsai)、蕭望德(Won-Der Shau)、林俊哲(LIN CHUN-CHE)、黃冠棠(Guan-Tarn Huang)、林肇堂(LIN JAW-TOWN)、彭成元(Peng, Cheng-Yuan)*，Alpha-fetoprotein response predicts treatment outcomes in patients with unresectable hepatocellular carcinoma receiving immune checkpoint inhibitors with or without tyrosine kinase inhibitors or locoregional therapies，American Journal of Cancer Research，2021 Dec，11(12):6173-6187 | 2021 . 12 |
| 17 | 許偉帆(Hsu, Wei-Fan)、蔡佩倩(Pei-Chien Tsai)、陳啟益(Chi-Yi Chen)、曾國枝(Kuo-Chih Tseng)、賴學洲(Hsueh-Chou Lai)、郭行道(Hsing-Tao Kuo)、洪肇宏(Chao-Hung Hung)、董水義(Shui-Yi Tung)、王景弘(Jing-Houng Wang)、陳志州(Jyh-Jou Chen)、李佩倫(Pei-Lun Lee)、簡榮南(Rong-Nan Chien)、林俊彥(Chun-Yen Lin)、楊基滐(Chi-Chieh Yang)、羅錦河(Gin-Ho Lo)、戴啟明(Chi?Ming Tai)、林志文(Chih-Wen Lin)、高嘉宏(Jia-Horng Kao)、劉俊人(Chun-Jen Liu)、劉振驊(Chen-Hua Liu)、顏聖烈(Sheng-Lei Yan)、白明忠(Ming-Jong Bair)、蘇維文(Wei-Wen Su)、朱正心(Cheng-Hsin Chu)、陳志仁(Chih-Jen Chen)、羅清池(Ching-Chu Lo)、鄭斌男(Pin-Nan Cheng)、邱彥程(Yen-Cheng Chiu)、王嘉齊(Chia-Chi Wang)、鄭錦翔(Jin-Shiung Cheng)、蔡維倫(Wei-Lun Tsai)、林漢傑(Han-Chieh Lin)、黃怡翔(Yi-Hsiang Huang)、黃志富(Jee-Fu Huang)、戴嘉言(Chia-Yen Dai)、莊萬龍(Wan-Long Chuang)、余明隆(Ming-Lung Yu)*、彭成元(Cheng-Yuan Peng)*，Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort)，JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY，2021 Oct，36(.10):2884-2892 | 2021 . 10 |
| 18 | 陳昇弘(Sheng-Hung Chen)、黃嘉琳(Chia-Lin Huang)、江宜平(I-Ping Chiang)、張孜菁(Tzu-Ching Chang)、王鴻偉(Hung-Wei Wang)、許偉帆(Wei-Fan Hsu)、蔡宗佑(Tsung-Yu Tsai)、彭成元(Cheng-Yuan Peng)*，Liver fibrosis regression correlates with downregulation in liver angiogenesis in chronic hepatitis C through viral eradication，EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY，2021 Sep，33(9):1209-1217 | 2021 . 09 |
| 19 | 許偉帆(Hsu, Wei-Fan)、張凱智(CHANG, KAI-CHIH)、陳德鴻(Te-Hung Chen)、林建宏(Chien-Hung Lin)、林膺峻(Lin,Ying-Chun)、蔡明宏(Ming-Hung Tsai)、陳旆聿(Pei-Yu Chen)、王鴻偉(Hung-Wei Wang)、朱家聲(Chia-Sheng Chu)、彭成元(Cheng-Yuan Peng)*，Comparison of 10 noninvasive models for predicting overall survival in patients with intermediate-stage hepatocellular carcinoma，MEDICINE，2021 Aug，100(33):e27000 | 2021 . 08 |
| 20 | 王鴻偉(Hung-Wei Wang)、莊伯恒(Po-Heng Chuang)、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao)、許偉帆(Hsu, Wei-Fan)、林俊哲(LIN CHUN-CHE)、黃冠棠(Guan-Tarn Huang)、林肇堂(LIN JAW-TOWN)、賴學洲(Hsueh-Chou Lai)*、彭成元(Cheng-Yuan Peng)*，On-Treatment Albumin-Bilirubin Grade: Predictor of Response and Outcome of Sorafenib-Regorafenib Sequential Therapy in Patients with Unresectable Hepatocellular Carcinoma，Cancers，2021 Jul，13(15):3758 | 2021 . 07 |
| 21 | 許偉帆(Hsu, Wei-Fan)、莊伯恒(Po-Heng Chuang)、陳政國(Cheng-Kuo Chen)、王鴻偉(Hung-Wei Wang)、蔡明宏(Ming-Hung Tsai)、蘇文邦(Wen-Pang Su)、陳浤燿(Hung-Yao Chen)、楊其穎(Chi-Ying Yang)、林俊哲(LIN CHUN-CHE)、黃冠棠(Guan-Tarn Huang)、林肇堂(LIN JAW-TOWN)、賴學洲(Hsueh-Chou Lai)*、彭成元(Cheng-Yuan Peng)*，Predictors of response and survival in patients with unresectable hepatocellular carcinoma treated with nivolumab: real-world experience，American Journal of Cancer Research，2020 Dec，10(12):4547-4560 | 2020 . 12 |
| 22 | 許偉帆(Wei-Fan Hsu)、林裕超(Yu-Chao Lin)、江宜平(I-Ping Chiang)、彭成元(Cheng-Yuan Peng)*，Gastric necrosis after nivolumab therapy in a patient with advanced hepatocellular carcinoma，DIGESTIVE AND LIVER DISEASE，2020 Sep，20(): | 2020 . 09 |
| 23 | 吳宜樺(Wu Yi-Hua)、許偉帆(Wei-Fan Hsu)*、楊其穎(Chi-Ying Yang)、張凱博(Kai-Po Chang)，Gastrointestinal Bleeding Caused by Hepatocellular Carcinoma in a Rare Case of Direct Invasion to the Duodenum，DIGESTIVE AND LIVER DISEASE，2020 Aug，52(): | 2020 . 08 |
| 24 | 許偉帆(Wei-Fan Hsu)、陳啟益(Chi-Yi Chen)、曾國枝(Kuo-Chih Tseng)、賴學洲(Hsueh-Chou Lai)、郭行道(Hsing-Tao Ku)、洪肇宏(Chao-Hung Hung)、董水義(Shui-Yi Tung)、王景弘(Jing-Houng Wang)、陳志州(Jyh-Jou Chen)、李佩倫(Pei-Lun Lee)、簡榮南(Rong-Nan Chien)、林俊彥(Chun-Yen Lin)、楊基滐(Chi-Chieh Yang)、羅錦河(Gin-Ho Lo)、戴啟明(Chi-Ming Ta)、林志文(Chih-Wen Lin)、高嘉宏(Jia-Horng Kao)、劉振驊(Chun-Jen Liu)、劉俊人(Chen-Hua Liu)、顏聖烈(Sheng-Lei Yan)、白明忠(Ming-Jong Bair)、蘇維文(Wei-Wen Su)、朱正心(Cheng-Hsin Chu)、陳志仁(Chih-Jen Chen)、羅清池(Ching-Chu Lo)、鄭斌男(Pin-Nan Cheng)、邱彥程(Yen-Cheng Chiu)、王嘉齊(Chia-Chi Wang)、鄭錦翔(Jin-Shiung Cheng)、蔡維倫(Wei-Lun Tsai)、林漢傑(Han-Chieh Lin)、黃怡翔(Yi-Hsiang Huang)、蔡佩倩(Pei-Chien Tsai)、黃志富(Jee-Fu Huang)、戴嘉言(Chia-Yen Dai)、莊萬龍(Wan-Long Chuang)、余明隆(Ming-Lung Yu)*、彭成元(Cheng-Yuan Peng)*，Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis，Scientific Reports，2020 Mar，10(1):5372 | 2020 . 03 |
| 25 | 陳昇弘(Sheng-Hung Chen)、賴學洲(Hsueh-Chou Lai)、江宜平(I-Ping Chiang)、蘇文邦(Wen-Pang Su)、林佳欣(Chia-Hsin Lin)、高榮達(Jung-Ta Kao)、莊伯恒(Po-Heng Chuang)、許偉帆(Wei-Fan Hsu)、王鴻偉(Hung-Wei Wang)、陳浤燿(Hung-Yao Chen)、黃冠棠(Guan-Tarn Huang)、彭成元(Cheng-Yuan Peng)*，Performance of Acoustic Radiation Force Impulse Elastography for Staging Liver Fibrosis in Patients With Chronic Hepatitis C After Viral Eradication，CLINICAL INFECTIOUS DISEASES，2020 Jan，70(1):114-122 | 2020 . 01 |
| 26 | (Hsien-Chih Wu)、(Chia-Lin Huang,)、王鴻偉(Hung-Wei Wang)、許偉帆(Wei-Fan Hsu)、蔡宗佑(Tsung-Yu Tsai)、陳昇弘(Sheng-Hung Chen)、彭成元(Cheng-Yuan Peng)*，Serum miR-21 correlates with the histological stage of chronic hepatitis B-associated liver fibrosis.，International Journal of Clinical and Experimental Pathology，2019 Dec，12(10):3819-3829 | 2019 . 12 |
| 27 | 許偉帆(Wei-Fan Hsu)、余詩涵(Shi-Hang Yu)、林肇堂(LIN JAW-TOWN)、吳肇卿(Jaw-Ching Wu)、侯明志(Ming-Chih Hou)、黃怡翔(Yi-Hsiang Huang)、(吳俊穎)*、彭成元(Cheng-Yuan Peng)*，Renal Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients with Liver Cirrhosis: A Nationwide Cohort Study，Gastroenterology Research and Practice，2019 Oct，2019(2019):1743290 | 2019 . 10 |
| 28 | 黃升騰(Sheng-Teng Huang)*、許偉帆(Wei-Fan Hsu)、黃紘森(Huang Hung-Sen)、顏加豪(Jia-hau Yen)、林美辰(Mei-Chen Lin)、彭成元(Cheng-Yuan Peng)、顏宏融(Hung-Rong Yen)*，Improved Survival in Hepatocellular Carcinoma Patients with Cardiac Arrhythmia by Amiodarone Treatment through Autophagy，INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES，2019 Aug，20(16):3978 | 2019 . 08 |
| 29 | 許偉帆(Wei-Fan Hsu)、賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)*、林佳欣(Chia-Hsin Lin)、莊伯恒(Po-Heng Chuang)、陳昇弘(Sheng-Hung Chen)、陳浤燿(Hung-Yao Chen)、王鴻偉(Hung-Wei Wang)、黃冠棠(Guan-Tarn Huang)、彭成元(Cheng-Yuan Peng)*，Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct-acting antiviral agents，BMC GASTROENTEROLOGY，2019 Apr，19(1):63 | 2019 . 04 |
| 30 | 李癸汌(Kuei-Chuan Lee)、許偉帆(Wei-Fan Hsu)、謝昀蓁(Yun-Cheng Hsieh)、詹哲彰(Che-Chang Chan)、楊盈盈(Ying-Ying Yang)、黃怡翔(Yi-Hsiang Huang)、侯明志(Ming-Chih Hou)、林漢傑(Han-Chieh Lin)*，Dabigatran Reduces Liver Fibrosis in Thioacetamide‑Injured Rats，DIGESTIVE DISEASES AND SCIENCES，2019 Jan，64(1):102-112 | 2019 . 01 |
| 31 | 許偉帆(Wei-Fan Hsu)、余承儒(Cheng-Ju Yu)*、葉俊杰(Chun-Chieh Yeh)、黃文信(Wen-Hsin Huang)、彭成元(Cheng-Yuan Peng)，Splenic cystic lymphangiomatosis in association with omental varices and portal hypertension，MEDICINE，2018 Oct，97(40):e12552-e12552 | 2018 . 10 |
| 32 | 陳冠至(Kuan-Chih Chen)、鍾承軒(Chen-Shuan Chung)、許偉帆(Wei-Fan Hsu)、(Tien-Yu Huang)、林政寬(Cheng-Kuan Lin)、李宗熙(Tzong-Hsi Lee)、翁孟慈(Meng-Tzu Weng)、(Cheng-Ming Chiu)、(Li-Chun Chang)*、邱瀚模(Han-Mo Chiu)，Identification of Risk Factors For Neoplastic Colonic Polyps In Young Adults With Bloody Stool In Comparison With Those Without Symptom，JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY，2018 Jul，33(7):1335-1340 | 2018 . 07 |
| 33 | 許偉帆(Wei-Fan Hsu)、陳春妃(Chuen-Fei Chen)、賴學洲(Lai, Hsueh-Chou)、蘇文邦(Wen-Pang Su)、林佳欣、莊伯恒(Po-Heng Chuang)、陳昇弘(Chen, Sheng-Hung)、陳浤燿(Chen, Ching-Hsiang)、王鴻偉(Hung-Wei Wang)、黃冠棠、彭成元(Peng, Cheng-Yuan)*，Trajectories of serum hepatitis B surface antigen kinetics in patients with chronic hepatitis B receiving long-term nucleos(t)ide analogue therapy，LIVER INTERNATIONAL，2018 Apr，38(4):627-635 | 2018 . 04 |
| 34 | 陳昇弘(Chen, Sheng-Hung)、賴學洲(Lai, Hsueh-Chou)、江宜平(Chiang, I-Ping)、蘇文邦(Wen-Pang Su)、林佳欣、高榮達(Kao, Jung-Ta)、莊伯恒(Po-Heng Chuang)、許偉帆(Wei-Fan Hsu)、王鴻偉(Hung-Wei Wang)、陳浤燿(Chen, Ching-Hsiang)、黃冠棠、彭成元(Peng, Cheng-Yuan)*，Changes in liver stiffness measurement using acoustic radiation force impulse elastography after antiviral therapy in patients with chronic hepatitis C，PLoS One，2018 Jan，13(1):e0190455-e0190455 | 2018 . 01 |
| 35 | 王鴻偉(Hung-Wei Wang)、彭成元(Cheng-Yuan Peng)*、賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、林佳欣、莊伯恒(Po-Heng Chuang)、陳昇弘(Sheng-Hung Chen)、陳景祥(Ching-Hsiang Chen)、許偉帆(Wei-Fan Hsu)、黃冠棠，New noninvasive index for predicting liver fibrosis in Asian patients with chronic viral hepatitis，Scientific Reports，2017 Jun，7(1):3259 | 2017 . 06 |
| 36 | 許偉帆(Wei-Fan Hsu)、沈立言(Lee-Yan Sheen)、林宏任(Lin Hung-jen)、張恒鴻(CHANG,HEN-HONG)*，A Review of Western and Traditional Chinese Medical Approaches to Managing Nonalcoholic Fatty Liver Disease，Evidence-based Complementary and Alternative Medicine，2016 Nov，2016(2016):1-12 | 2016 . 11 |
| 37 | 許偉帆(Wei-Fan Hsu)、梁程超(Cheng-Chao Liang)、林政寬(Cheng-Kuan Lin)、李宗熙(Tzong-Hsi Lee)、鍾承軒(Chen-Shuan Chung)*，A modified bowel preparation protocol improves the quality of bowel cleansing for colonoscopy，Advances in Digestive Medicine，2016 Mar，3(3):144-147 | 2016 . 03 |
| 38 | 施映伃(Ying-Yu Shih)、梁程超(Cheng-Chao Liang)、林政寬(Cheng-Kuan Lin)、許偉帆(Wei-Fan Hsu)、吳建陞(Chien-Sheng Wu)、鍾承軒(Chen-Shuan Chung)*，Ileal ulcers in a patient with Henoch- Scho¨nlein purpura，Advances in Digestive Medicine，2015 Dec，2(4):145-148 | 2015 . 12 |
| 39 | 鍾承軒(Chen-Shuan Chung)、林政寬(Cheng-Kuan Lin)、梁程超(Cheng-Chao Liang)、許偉帆(Wei-Fan Hsu)、李宗熙(Tzong-Hsi Lee)*，Intentional examination of esophagus by narrow-band imaging endoscopy increases detection rate of cervical inlet patch，DISEASES OF THE ESOPHAGUS，2015 Oct，28(7):666-672 | 2015 . 10 |
| 40 | 鍾承軒(Chen-Shuan Chung)、林政寬(Cheng-Kuan Lin)、許偉帆(Wei-Fan Hsu)、李宗熙(Tzong-Hsi Lee)、王秀伯(Hsiu-Po Wang)、梁程超(Cheng-Chao Liang)*，Gastroenterology: Pneumomediastinum and pneumoperitoneum after peroral endoscopic myotomy: Complications or normal post-operative changes? (WOS資料庫文章類型:Editorial Material，JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY，2015 Oct，30(10):1447-1447 | 2015 . 10 |
| 41 | 許偉帆(Wei-Fan Hsu)、(Cheng-Yu Lo)、(Chen-Shuan Chung)*，A rare cause of tarry stool and ileus，GASTROINTESTINAL ENDOSCOPY，2015 Aug，82(2):415-417 | 2015 . 08 |
| 42 | 許偉帆(Wei-Fan Hsu)、楊家瑞(Chia-Jui Yang)、林政寬(Cheng-Kuan Lin)*，An 86-year-old man with intermittent fever for 1 month，Advances in Digestive Medicine，2015 Jun，2(2):79-82 | 2015 . 06 |
| 43 | 施映伃(Ying-Yu Shih)、許偉帆(Wei-Fan Hsu)、林建助(Chien-Chu Lin)*，Foreign Body Related Micro-Perforation Managed by Colonoscopy after A Failed Laparoscopic Exploration – A Case Report，內科學誌，2015 Feb，26(1):35-38 | 2015 . 02 |
| 44 | 許偉帆(Wei-Fan Hsu)、曾旭明(Yuk-Ming Tsang)、鄧仲仁(Chung-Jen Teng)、鍾承軒(Chen-Shuan Chung)*，Protein C deficiency related obscure gastrointestinal bleeding treated by enteroscopy and anticoagulant therapy，WORLD JOURNAL OF GASTROENTEROLOGY，2015 Jan，21(3):1024-1027 | 2015 . 01 |
| 45 | 許偉帆(Wei-Fan Hsu)、鍾承軒(Chen-Shuan Chung)、彭渝森(Yu-Sen Peng)、梁程超(Cheng-Chao Liang)*，Clinical Use of Angiotensin Converting Enzyme and Angiotensin Receptor Blocker in Patients with Liver Cirrhosis，內科學誌，2014 Apr，25(2):1-7 | 2014 . 04 |
| 46 | 許偉帆(Wei-Fan Hsu)、(Chien-Chu Lin)*，A MAN WITH PRODUCTIVE COUGH，臺灣消化醫學雜誌，2013 Dec，30(4):324-325 | 2013 . 12 |
| 47 | 許偉帆(Wei-Fan Hsu)、林建助(Chien-Chu Lin)、張耿銘(Keng-Ming Chang)、李宗熙(Tzong-Hsi Lee)*，Primary aortoesophageal fistula: A rare but fatal cause of upper gastrointestinal bleeding，Journal of Digestive Diseases，2013 Dec，14(12):676-678 | 2013 . 12 |
| 48 | 許偉帆(Wei-Fan Hsu)、吳建陞(Chien-Sheng Wu)、吳建明(Jiann-Ming Wu)、鍾承軒(Chen-Shuan Chung)*，Ileal Crohn’s disease with perforation misdiagnosed as ruptured appendicitis: A case report，JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION，2013 Oct，112(10):652-653 | 2013 . 10 |
| 49 | (Chen-Shuan Chung)、(Li-Jen Liao)、(Wu-Chia Lo)、(Yueh-Hung Chou)、(Yi-Chen Chang)、(Yu-Chin Lin)、許偉帆(Wei-Fan Hsu)、(Pei-Wei Shueng)、(Tzong-Hsi Lee)*，Risk factors for second primary neoplasia of esophagus in newly diagnosed head and neck cancer patients: a case–control study，BMC GASTROENTEROLOGY，2013 Oct，13():154 | 2013 . 10 |
| 50 | 許偉帆(Wei-Fan Hsu)、林耿立(KENG-LI LIN)、黃俊傑(CHUN-CHIEH HUANG)、周岳弘(YUEH-HUNG CHOU)、梁程超(CHENG-CHAO LIANG)*，SIGNET-RING CELL CARCINOMA OF THE APPENDIX: REPORT OF A CASE，臺灣消化醫學雜誌，2013 Sep，30(3):272-276 | 2013 . 09 |
| 51 | 許偉帆(Wei-Fan Hsu)、鍾承軒(Chen-Shuan Chung)、許永隆(Yeong-Long Hsu)、張厚台(Hou-Tai Chang)*，Esophageal milk curd in an adult: a rare cause of sustained pneumonia，中華民國重症醫學雜誌，2012 Dec，13(4):198-202 | 2012 . 12 |
研討會論文
|
研討會論文／Conference Papers (發表主題或論文名稱，研討會名稱，演講地點，研討會期間，受邀演講題目) |
日期 | |
| 1 | 肝細胞癌患者接受Atezolizumab和Bevacizumab後造成腫瘤溶解症候群的案例分析，台灣內科醫學會113年會員大會暨學術演講會，台大醫院國際會議中心，2024.11.30~2024.12.01， | 2024 . 11 |
| 2 | Risk Stratification of Liver-Related Events and Hepatocellular Carcinoma After Antiviral Treatment Using Baseline and Post-Treatment Liver Stiffness，Taiwan Digestive Disease Week (TDDW) 2024，Kaohsiung，2024.10.05~2024.10.06， | 2024 . 10 |
| 3 | Long-term dynamic changes of insulin resistance and lipid profiles in patients with hepatitis C viral eradication，2024TDDW台灣消化醫學週，高雄萬豪飯店，2024.10.04~2024.10.06， | 2024 . 10 |
| 4 | Prediction model for risk of hepatocellular carcinoma and liver-related events after hepatitis C viral eradication，2024TDDW台灣消化醫學週，高雄萬豪飯店，2024.10.04~2024.10.06， | 2024 . 10 |
| 5 | Viral Eradication Decreases the Incidences of New-onset Liver Cirrhosis and Major Liver-related Events in Patients with Chronic Hepatitis C，2024 APASL Single Topic Conference on MAFLD (2024 APASL STC on MAFLD)，Kaohsiung Exhibition Center (KEC)，2024.06.29~2024.06.30， | 2024 . 06 |
| 6 | ，2024 The Asian Pacific Association for the Study of the Liver (APASL) Single Topic Conference (STC) on MAFLD，Kaohsiung Exhibition Center，2024.06.28~2024.06.30，The Impact of Hepatitis C on Patients’ Metabolism | 2024 . 06 |
| 7 | Hepatic decompensation as an aetiology-dependent determinant of mortality in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab，EASL (the European Association for the Study of the Liver) Congress 歐洲肝臟醫學會年會 2024，Milan, Italy，2024.06.05~2024.06.08， | 2024 . 06 |
| 8 | Risk Stratification for Hepatocellular Carcinoma after Hepatitis C Cure using Metabolic and Fibrotic Biomarkers，APASL (The Asian Pacific Association for the Study of the Liver) STC on MAFLD 2024，Kaohsiung，2024.06.29~2024.06.30， | 2024 . 06 |
| 9 | Components of Cardiometabolic Criteria Predict Liver-Related Events in Patients Cured of Hepatitis C Virus，2024 Joint International Conference of Taiwan Liver Cancer Association and Taiwan Academy of Tumor Ablation，台中金典酒店，2024.05.18~2024.05.19， | 2024 . 05 |
| 10 | ，中華民國一一三年台灣消化系聯合學術演講年會，高雄醫學大學，2024.03.23~2024.03.24，The role and value of algorithms in hepatocellular carcinoma patient journey | 2024 . 03 |
| 11 | The Impact of Steatotic Liver Disease on Liver-Related Events in Patients Cured of Hepatitis C Virus，2024 The Asian Pacific Association for the Study of the Liver Annual Meeting，Kyoto International Conference Hall，2024.03.27~2024.03.31， | 2024 . 03 |
| 12 | 病毒根除降低慢性C肝新生肝硬化及肝臟相關併發症發生率，中華民國113年消化系聯合學術演講年會，高雄醫學大學，2024.03.23~2024.03.24， | 2024 . 03 |
| 13 | Post-progression outcomes of advanced HCC patients (aHCC pts) treated with first-line atezolizumab/bevacizumab (A/B)，European Society for Medical Oncology (ESMO) Congress 2023 歐洲腫瘤學會年會，IFEMA Madrid, Madrid, Spain，2023.10.20~2023.10.24， | 2023 . 10 |
| 14 | The performance of the collagen proportionate area (CPA), Enhanced Liver Fibrosis (ELF) test, FIB-4, and Mac-2 binding protein glycosylation isomer (M2BPGi) in predicting the liver fibrosis stage in patients with chronic hepatitis C who received paired biopsies before and after antiviral therapy，2023 Taiwan Digestive Disease Week (2023 TDDW) 台灣消化醫學週，國立中山大學，2023.09.23~2023.09.24， | 2023 . 09 |
| 15 | Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT criteria，TDDW2023台灣消化醫學週，國立中山大學，2023.09.23~2023.09.24， | 2023 . 09 |
| 16 | Post-treatment factors predict liver-related events and hepatocellular carcinoma in cured hepatitis C patients: a multicenter study，2023TDDW台灣消化醫學週，國立中山大學，2023.09.23~2023.09.24， | 2023 . 09 |
| 17 | Metabolic-Associated Fatty Liver Disease and Long-Term Risk of Hepatocellular Carcinoma in Treated Chronic Hepatitis B，2023 Taiwan Digestive Disease Week (2023 TDDW) 台灣消化醫學週，國立中山大學，2023.09.23~2023.09.24， | 2023 . 09 |
| 18 | The Utility of Diabetes Mellitus Diagnosis and Post-Sustained Virologic Response Liver Stiffness Values in Predicting the Risk of Post-SVR Hepatocellular Carcinoma in Patients with Chronic Hepatitis C 慢性C型肝炎患者糖尿病診斷和持續病毒學反應後肝硬度值在預測持續病毒學反應後肝細胞癌風險中的意義和效用，Taiwan Digestive Disease Week 2023，National Sun Yat-sen University, Kaohsiung，2023.09.23~2023.09.24， | 2023 . 09 |
| 19 | ，2023 TASL (Taiwan Association for the Study of the Liver) 台灣肝臟研究學會 STC (single topic conference)，國立成功大學醫學院 成杏廳，2023.07.01~2023.07.02，Metabolic dysfunction-Associated Fatty Liver Disease in Patients with Chronic Hepatitis C | 2023 . 07 |
| 20 | Validation of the CRAFITY score in patients with hepatocellular carcinoma treated with atezolizumab and bevacizumab，EASL (the European Association for the Study of the Liver) Congress 歐洲肝臟醫學會年會 2023，Messe Wien (維也納展覽中心), Vienna, Austria，2023.06.21~2023.06.24， | 2023 . 06 |
| 21 | The von Willebrand factor/platelet ratio as a surrogate biomarker of spleen stiffness measurement in patients with chronic hepatitis C after antiviral treatment，中華民國112 年消化系聯合學術演講年會 TDDW 2023，台北榮民總醫院，2023.03.25~2023.03.26， | 2023 . 03 |
| 22 | Metabolic dysfunction but not echo liver steatosis increases the risk of liver related events in patients with cured hepatitis C，中華民國一一二年台灣消化系聯合學術演講年會，台北榮民總醫院，2023.03.25~2023.03.26， | 2023 . 03 |
| 23 | B型肝炎表面抗原軌跡與抗原下降預測長期接受核苷酸類似物治療慢性B型肝炎患者療效，中華民國一一二年台灣消化系聯合學術演講年會，台北榮民總醫院，2023.03.25~2023.03.26， | 2023 . 03 |
| 24 | Metabolic Dysfunction but Not Ultrasonographic Hepatic Steatosis Increases the Risk of Liver-Related Events in Patients with Cured Hepatitis C，2023 The Asian Pacific Association for the Study of the Liver Annual Meeting，台北國際會議中心(TICC)，2023.02.15~2023.02.19， | 2023 . 02 |
| 25 | Combined CRAFITY Score and A-fetoprotein Response Predicts Treatment Outcomes in Patients with Unresectable Hepatocellular Carcinoma Receiving Anti-programmed Death-1 Blockade–based Immunotherapy，2023 The Asian Pacific Association for the Study of the Liver Annual Meeting，台北國際會議中心(TICC)，2023.02.15~2023.02.19， | 2023 . 02 |
| 26 | Trajectories of Serum Hepatitis B Surface Antigen Kinetics and Surface Antigen Decline Predict Treatment Outcomes in Patients with Chronic Hepatitis B Receiving Long-term Nucleos(t)ide Analogue Therapy，2023 The Asian Pacific Association for the Study of the Liver Annual Meeting，台北國際會議中心(TICC)，2023.02.15~2023.02.19， | 2023 . 02 |
| 27 | ，C手護肝 肝淨台灣 20221023，台中林皇宮，2022.10.23~2022.10.23，台中監獄C肝根除經驗分享 | 2022 . 10 |
| 28 | Modified albumin–bilirubin model for stratifying survival in patients with hepatocellular carcinoma receiving anticancer therapy，2022TDDW台灣消化醫學週，台大國際會議中心，2022.09.24~2022.09.25， | 2022 . 09 |
| 29 | Pretreatment and posttreatment spleen stiffness values as significant predictors of liver-related events in patients with chronic hepatitis C after direct-acting antiviral therapy治療前及治療後脾臟硬度測量可做為C型肝炎病患接受DAA治療後肝臟相關事件之顯著預測因子，2022 Taiwan Digestive Disease Week (2022 TDDW)，NTUH International Convention Center Taipei，2022.09.24~2022.09.25， | 2022 . 09 |
| 30 | Predictors of survival outcomes in patients with unresectable hepatocellular carcinoma treated with 1st line systemic therapy with lenvatinib: one single center real-world experience，2022 Taiwan Digestive Disease Week (2022 TDDW)，台大國際會議中心，2022.09.24~2022.09.25， | 2022 . 09 |
| 31 | Lenvatinib plus pembrolizumab for patients with unresectable hepatocellular carcinoma as 1st line systemic combination therapy: one single center real-world experience，2022 Taiwan Digestive Disease Week (2022 TDDW)，台大國際會議中心，2022.09.24~2022.09.25， | 2022 . 09 |
| 32 | Modified cutoffs for ALBI grade for patients with early, intermediate, or advanced hepatocellular carcinoma，2022 Asian Pacific Association for the Study of the Liver Single Topic Conference on Hepatocellular Carcinoma，台大醫院國際會議中心，2022.06.23~2022.06.25， | 2022 . 06 |
| 33 | Posttreatment nonalcoholic fatty liver disease fibrosis scores for predicting liver related complications in patients with chronic hepatitis C receiving direct acting antiviral agents，2022 Asian Pacific Association for the Study of the Liver Single Topic Conference on Hepatocellular Carcinoma，台大醫院國際會議中心，2022.06.23~2022.06.25， | 2022 . 06 |
| 34 | Concurrent immune checkpoint inhibitor and tyrosine kinase inhibitor therapy yields better outcome than immune checkpoint inhibitor monotherapy in patients with advanced hepatocellular carcinoma，2022 Asian Pacific Association for the Study of the Liver Single Topic Conference on Hepatocellular Carcinoma，台大醫院國際會議中心，2022.06.23~2022.06.25， | 2022 . 06 |
| 35 | Clinical characteristics of patients receiving hepatitis B viral chemoprophylaxis after the implementation of expanded reimbursement criteria，中華民國一一一年台灣消化系聯合學術演講年會，高雄萬豪飯店，2022.03.26~2022.03.27， | 2022 . 03 |
| 36 | Comparison and correlation of fibrosis stage assessment by collagen proportionate area (CPA) and noninvasive fibrosis indices in patients with chronic hepatitis B: a pilot study，中華民國一一一年台灣消化系聯合學術演講年會，高雄萬豪酒店，2022.03.26~2022.03.27， | 2022 . 03 |
| 37 | Post-therapeutic nonalcoholic fatty liver disease fibrosis scores predicts liver-related complications in chronic hepatitis C patients receiving oral agents，中華民國一一一年台灣消化系聯合學術演講年會，高雄萬豪飯店，2022.03.26~2022.03.27， | 2022 . 03 |
| 38 | Utility of long-term posttreatment liver stiffness follow-ups in prediction of liver-related events in patients with chronic hepatitis C – Combined α-fetoprotein and liver stiffness far beyond SVR to predict longer-term liver-related events in CHC – a rea，2021 Taiwan Digestive Disease Week，Online Conference (during COVID-19 pandemic)，2021.09.24~2021.09.26， | 2021 . 09 |
| 39 | Concurrent immune checkpoint inhibitor and tyrosine kinase inhibitor therapy yields better outcome than immune checkpoint inhibitor monotherapy in patients with advanced hepatocellular carcinoma，2021TDDW台灣消化醫學週，台大醫院國際會議中心，2021.09.25~2021.09.26， | 2021 . 09 |
| 40 | HCV eradication decreases the risks of liver cirrhosis and cirrhosis-related complications，中華民國一一O年台灣消化系聯合學術演講年會，中國醫藥大學英才校區，2021.03.27~2021.03.28， | 2021 . 03 |
| 41 | Comparison of ten liver functional reserve models for overall survival in patients with intermediate-stage hepatocellular carcinoma and different stratification，中華民國一一O年台灣消化系聯合學術演講年會，中國醫藥大學英才校區，2021.03.27~2021.03.28， | 2021 . 03 |
| 42 | Longitudinal changes in acoustic radiation force impulse (ARFI) values in patients with chronic hepatitis B receiving nucleos(t)ide analogue therapy，中華民國一一O年台灣消化系聯合學術演講年會，中國醫藥大學英才校區，2021.03.27~2021.03.28， | 2021 . 03 |
| 43 | 介白素10預測慢性B型肝炎病人接受貝樂克治療發生早期血清表面抗原濃度下降，中華民國一一○年消化系聯合學術演講年會，中國醫藥大學英才校區，2021.03.27~2021.03.28， | 2021 . 03 |
| 44 | Nivolumab therapy with and without combination of tyrosine kinase inhibitor for patients with unresectable hepatocellular carcinoma，中華民國一一O年台灣消化系聯合學術演講年會，中國醫藥大學英才校區，2021.03.27~2021.03.28， | 2021 . 03 |
| 45 | Baseline albumin-total bilirubin (ALBI) score predicts incident or recurrent hepatocellular carcinoma in chronic hepatitis C patients receiving direct-acting antiviral agents，中華民國一一O年台灣消化系聯合學術演講年會，中國醫藥大學英才校區，2021.03.27~2021.03.28， | 2021 . 03 |
| 46 | Sofosbuvir and velpatasvir (Epclusa®) to treat prisoners with chronic hepatitis C- an experience in a Taichung medical center，中華民國一一O年台灣消化系聯合學術演講年會，中國醫藥大學英才校區，2021.03.27~2021.03.28， | 2021 . 03 |
| 47 | Direct-acting antiviral therapies in patients with HIV/HCV coinfection，2021台灣消化系聯合學術演講年會，中國醫藥大學，2021.03.27~2021.03.28， | 2021 . 03 |
| 48 | ，110年 01 月中部地區消化系同好會，頂粵極品，2021.01.7 ~2021.01.7 ，HBV: Updated indication of TAF and local reimbursement criteria expansion | 2021 . 01 |
| 49 | Longitudinal Analyses of the Biphasic Kinetics in Liver and Spleen Stiffness Values in Hepatitis C Virus-Infected Patients on and off Direct-Acting Antiviral Therapies 分析接受Direct-Acting Antivirals治療之C型肝炎病患治療中及治療後肝臟及脾臟硬度跨越時間之雙相變化，Taiwan Digestive Disease Week (TDDW) 2020，National Taiwan University Hospital International Convention Center，2020.09.25~2020.09.27， | 2020 . 09 |
| 50 | Post-treatment liver stiffness measurement using acoustic radiation force impulse predicts incident hepatocellular carcinoma in chronic hepatitis C patients with advanced liver fibrosis，2020台灣消化系醫學週，台大醫院國際會議中心，2020.09.26~2020.09.27， | 2020 . 09 |
| 51 | Outcome of HCV infected prisoners under direct-acting antiviral agent treatment in Taiwan.，2020TDDW台灣消化醫學週，台大醫院國際會議中心，2020.09.25~2020.09.27， | 2020 . 09 |
| 52 | Predictors of response and survival in patients with unresectable hepatocellular carcinoma treated with nivolumab: Real-world experience，2020台灣肝癌醫學會與台灣腫瘤消融醫學會聯合國際研討會，財團法人張榮發基金會國際會議中心11樓，2020.08.8 ~2020.08.9 ， | 2020 . 08 |
| 53 | Predictive factors for incident or recurrent hepatocellular carcinoma in patients with chronic hepatitis C after direct-acting antiviral therapy，中華民國一O九年消化系聯合學術演講年會，國防醫學中心，2020.07.11~2020.07.12， | 2020 . 07 |
| 54 | Nivolumab for hepatocellular carcinoma: a combined experience at two hospitals in central Taiwan，中華民國一O九年消化系聯合學術演講年會，國防醫學中心，2020.07.11~2020.07.12， | 2020 . 07 |
| 55 | Kinetics in Spleen Stiffness Values through Elastography in Patients with Chronic Hepatitis C on and off Treatments with Direct-acting Antivirals 接受Direct-acting Antivirals治療之慢性C型肝炎病患治療中及治療後脾臟硬度值變化之相關因子，2019 Taiwan Digestive Disease Week, TDDW，Kaohsiung Exhibition Center, Kaohsiung，2019.09.27~2019.09.29， | 2019 . 09 |
| 56 | Incidence of diabetes mellitus and long-term glycemic control in patients with chronic hepatitis C receiving direct-acting antiviral therapy，2019台灣消化系醫學週，高雄展覽館，2019.09.27~2019.09.29， | 2019 . 09 |
| 57 | Sustained virological response to pegylated interferon plus ribavirin therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis in patients with chronic hepatitis C，2019台灣消化系醫學週，高雄展覽館，2019.09.27~2019.09.29， | 2019 . 09 |
| 58 | Early and late Hepatitis B surface antigen declines predict treatment response to long-term nucleos(t)ide analogue Therapy in Chronic Hepatitis B patients，中華民國一○八年消化系聯合學術演講年會，國防醫學中心，2019.03.30~2019.03.31， | 2019 . 03 |
| 59 | Dynamic changes in glomerular filtration rate during and at 12 weeks after direct-acting antiviral therapy in patients with chronic hepatitis C，中華民國一○八年消化系聯合學術演講年會，國防醫學中心，2019.03.30~2019.03.31， | 2019 . 03 |
| 60 | Real-world efficacy and safety of LDV/SOF treatment in HCV-1 and HCV-2 patients in Taiwan，中華民國一O八年消化系聯合學術演講年會，國防醫學中心，2019.03.30~2019.03.31， | 2019 . 03 |
| 61 | Direct-acting antiviral agents in the treatment of chronic hepatitis C experience from China Medical University Hospital，中區消化系同好會 (107/11)，裕元花園酒店4F東側包廂，2018.11.01~2018.11.01， | 2018 . 11 |
| 62 | Direct-acting antiviral agents in hepatitis C patients with liver cirrhosis and Child-Pugh score ≥6，2018台灣消化系醫學週，台大醫院國際會議中心，2018.09.29~2018.09.30， | 2018 . 09 |
| 63 | Insulin resistance and lipid profile in chronic hepatitis C patients treated with direct-acting antiviral agents，2018台灣消化系醫學週，台大醫院國際會議中心，2018.09.29~2018.09.30， | 2018 . 09 |
| 64 | Fecal microbiota transplantation in clostridium difficile infection and pseudomembranous colitis: an experience of a medical center in Taiwan，2018Taiwan Digestive disease week(TDDW)台灣消化醫學週 Evolution and Revolution of Digestive Disease，台大醫院國際會議中心，2018.09.29~2018.09.30， | 2018 . 09 |
| 65 | Fatty metamorphosis increases liver stiffness and noninvasive indices of liver fibrosis in patients with chronic hepatitis C，2018台灣消化系醫學週，台大醫院國際會議中心，2018.09.29~2018.09.30， | 2018 . 09 |
| 66 | SPLEEN STIFFNESS AND SPLENIC INDEX PREDICT ESOPHAGEAL VARICES IN PATIENTS WITH LIVER CIRRHOSIS，2018 APASL Single Topic Conference on Hepatitis B Virus Taipei，Taipei International Convention Center，2018.06.22~2018.06.24， | 2018 . 06 |
| 67 | Spleen stiffness and platelet count predict esophageal varices in patients with liver cirrhosis，中華民國一O七年台灣消化系聯合學術演講年會，台大醫院國際會議中心，2018.03.24~2018.03.25， | 2018 . 03 |
| 68 | Treatment with direct-acting anti-viral agents is associated with increased platelet counts in chronic hepatitis C patients without cirrhosis，2017台灣消化系醫學週，台大醫院國際會議中心，2017.09.30~2017.10.01， | 2017 . 09 |
| 69 | Long-term serum HBsAg kinetics in genotype B or C infected HBeAg-positive and –negative chronic hepatitis B patients following Pegasys therapy，2017台灣消化系醫學週，台大醫院國際會議中心，2017.09.30~2017.10.01， | 2017 . 09 |
| 70 | Glycohemoglobin, sugar, insulin resistance, and lipid profile in chronic hepatitis C patients treated with direct-acting antiviral agents，中華民國一○六年消化系聯合學術演講年會，台中榮民總醫院，2017.03.18~2017.03.19， | 2017 . 03 |
| 71 | C型肝炎患者接受直接作用抗病毒藥物前後糖化血色素、血糖、胰島素阻抗、與血脂肪的變化，中華民國一○六年消化系聯合學術演講年會，臺中榮民總醫院，2017.03.18~2017.03.19， | 2017 . 03 |
| 72 | Group-based trajectory model to predict hepatitis B surface antigen loss during nucleos(t)ide analogue therapy in chronic hepatitis B patients，2016 TDDW 台灣消化醫學週，台北，2016.10.01~2016.10.02， | 2016 . 10 |
| 73 | An Experience of Complex Herbal Formula in a Screening Platform for Human Biopsy.，The 15th Meeting of the Consortium for Globalization of Chinese Medicine，Taipei，2016.08.22~2016.08.26， | 2016 . 08 |
| 74 | The Child-Turcotte-Pugh numeric score of 6 or more has influence on survival in patients with hepatocellular carcinoma after curatively hepatic resection，APDW 2015，台北國際會議中心，2015.12.03~2015.12.06， | 2015 . 12 |
專書
暫無資料研究計畫
|
研究計畫／Research Grant (研究類型，研究計畫代號，主持人，補助或委託單位名稱，計畫名稱，計畫期間) |
日期 | |
| 1 | 個別型，DMR-113-013，彭成元(Peng, Cheng-Yuan)、謝佳宏(Chia-Hung Hsieh)，附醫院內計畫，鐵依賴型細胞死亡在非酒精性脂肪肝炎扮演重要角色，2023.8.1~2024.7.31 | 2023 . 08 |
| 2 | 個別型，NSTC 112-2314-B-039-025-MY3，謝佳宏(Chia-Hung Hsieh)、許偉帆(Hsu, Wei-Fan)，科技部，鐵依賴型細胞死亡xCT轉運蛋白失能是糖尿病與脂肪肝的主要貢獻者，2023.8.1~2024.7.31 | 2023 . 08 |
| 3 | 個別型，MOST 111-2314-B-039-061-MY3，謝佳宏(Chia-Hung Hsieh)、彭成元(Peng, Cheng-Yuan)，科技部，鐵依賴型細胞死亡典型調控者系統Xc-在非酒精性脂肪肝炎扮演重要角色，2023.8.1~2024.7.31 | 2023 . 08 |
| 4 | 個別型，MOST 111-2314-B-039-061-MY3，謝佳宏(Chia-Hung Hsieh)、彭成元(Peng, Cheng-Yuan)，科技部，鐵依賴型細胞死亡典型調控者系統Xc-在非酒精性脂肪肝炎扮演重要角色，2022.8.1~2023.7.31 | 2022 . 08 |
| 5 | 個別型，MOST 110-2314-B-039-046，馬文隆(Wen-Lung Ma)、鄭維中(Cheng, Wei-Chung)、彭成元(Cheng-Yuan Peng)、許偉帆(Hsu, Wei-Fan)，科技部，探討代謝體學之生物特徵在Ｂ型肝炎病毒所介導的肝纖維化及肝硬化之角色，2021.8.1~2022.7.31 | 2021 . 08 |
| 6 | 個別型，DMR-111-030，彭成元(Cheng-Yuan Peng)、李宗貴(Chong-Kuei Lii)，附醫院內計畫，果糖與葡萄糖在非酒精性脂肪肝進展的不同角色 (第二年)，2021.8.1~2022.7.31 | 2021 . 08 |
| 7 | 個別型，DMR-110-024，彭成元(Cheng-Yuan Peng)、李宗貴(Chong-Kuei Lii)，附醫院內計畫，果糖與葡萄糖在非酒精性脂肪肝進展的不同角色，2020.8.1~2021.7.31 | 2020 . 08 |
| 8 | 個別型，DMR-109-252，，附醫院內計畫，ALDH2在非酒精性脂肪肝扮演的角色(第三年)，2020.7.10~2020.12.31 | 2020 . 07 |
| 9 | 臨床試驗與研究計畫，CMUH106-REC3-134，賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、陳浤燿(Hung-Yao Chen)、陳昇弘(Chen, Sheng-Hung)、王鴻偉(Hung-Wei Wang)、許偉帆(Hsu, Wei-Fan)，，以Elbasvir/Grazoprevir治療未曾接受治療以及曾接受治療的慢性C型肝炎病毒基因亞型1b感染之血液透析患者，2020.1.1~2020.12.31 | 2020 . 01 |
| 10 | 臨床試驗與研究計畫，CMUH108-REC2-038，陳尚文(Shang-Wen Chen)、彭成元(Cheng-Yuan Peng)、賴學洲(Hsueh-Chou Lai)、許偉帆(Hsu, Wei-Fan)、蕭望德(Won-Der Shau)、陳德鴻(Te-Hung Chen)，，比較肝動脈化學栓塞療法後未達完全緩解時合併立體定位燒灼性放射治療或繼續肝動脈化學栓塞療法的臨床隨機對照試驗，2020.1.1~2020.12.31 | 2020 . 01 |
| 11 | 個別型，DMR-109-017，彭成元(Cheng-Yuan Peng)、蔡文正(Tsai, Wen-Chen)，附醫院內計畫，C型肝炎合併糖尿病患者接受抗病毒藥物治療前後腎功能、血糖、與血脂肪變化，2019.8.1~2020.7.31 | 2019 . 08 |
| 12 | 個別型，DMR-108-225，，附醫院內計畫，ALDH2在非酒精性脂肪肝扮演的角色(第二年)，2019.6.10~2019.12.31 | 2019 . 06 |
| 13 | 臨床試驗與研究計畫，CMUH106-REC3-134，賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、陳浤燿(Hung-Yao Chen)、陳昇弘(Sheng-Hung Chen)、王鴻偉(Hung-Wei Wang)、許偉帆(Wei-Fan Hsu)，，以Elbasvir/Grazoprevir治療未曾接受治療以及曾接受治療的慢性C型肝炎病毒基因亞型1b感染之血液透析患者，2019.1.1~2019.12.31 | 2019 . 01 |
| 14 | 臨床試驗與研究計畫，CMUH108-REC2-038，陳尚文(Shang-Wen Chen)、彭成元(Cheng-Yuan Peng)、賴學洲(Hsueh-Chou Lai)、許偉帆(Wei-Fan Hsu)、蕭望德(Won-Der Shau)、陳德鴻(Te-Hung Chen)，，比較肝動脈化學栓塞療法後未達完全緩解時合併立體定位燒灼性放射治療或繼續肝動脈化學栓塞療法的臨床隨機對照試驗，2019.1.1~2019.12.31 | 2019 . 01 |
| 15 | 個別型，DMR-108-018，彭成元(Cheng-Yuan Peng)、徐婕琳(Hsu, Jye-Lin)，附醫院內計畫，使用核苷酸類似物B型肝炎患者的肝臟免疫微環境，2018.8.1~2019.7.31 | 2018 . 08 |
| 16 | 個別型，DMR-107-211，，附醫院內計畫，ALDH2在非酒精性脂肪肝扮演的角色，2018.4.16~2018.12.31 | 2018 . 04 |
| 17 | 臨床試驗與研究計畫，CMUH106-REC1-157，賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、王鴻偉(Hung-Wei Wang)、許偉帆(Wei-Fan Hsu)、陳昇弘(Sheng-Hung Chen)、陳浤燿(Hung-Yao Chen)、莊伯恒(Po-Heng Chuang)，附醫廠商計畫，探討8週或12週elbasvir合併grazoprevir對於C型肝炎病毒基因型1b無治療經驗且有輕微肝纖維化患者之療效差異:開放隨機分配性試驗(EGALITE)，2018.1.1~2018.12.31 | 2018 . 01 |
| 18 | 臨床試驗與研究計畫，CMUH106-REC3-134，賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、陳浤燿(Hung-Yao Chen)、陳昇弘(Sheng-Hung Chen)、王鴻偉(Hung-Wei Wang)、許偉帆(Wei-Fan Hsu)，附醫廠商計畫，以Elbasvir/Grazoprevir治療未曾接受治療以及曾接受治療的慢性C型肝炎病毒基因亞型1b感染之血液透析患者，2018.1.1~2018.12.31 | 2018 . 01 |
| 19 | 臨床試驗與研究計畫，CMUH106-REC3-054，彭成元(Peng, Cheng-Yuan)、賴學洲(Lai, Hsueh-Chou)、蘇文邦(Wen-Pang Su)、莊伯恒(Po-Heng Chuang)、王鴻偉(Hung-Wei Wang)、陳景祥、陳昇弘(Chen, Sheng-Hung)、許偉帆(Wei-Fan Hsu)，附醫廠商計畫，針對先前接受全身性治療的晚期肝細胞癌亞洲受試者，比較Pembrolizumab併用最佳支持性照護相對於安慰劑併用最佳支持性照護，作為第二線療法的一項隨機分配、雙盲第三期試驗(KEYNOTE-394)，2017.1.1~2017.12.31 | 2017 . 01 |
| 20 | 臨床試驗與研究計畫，CMUH105-REC1-141，賴學洲(Lai, Hsueh-Chou)、蘇文邦(Wen-Pang Su)、陳昇弘(Chen, Sheng-Hung)、陳景祥、王鴻偉(Hung-Wei Wang)、許偉帆(Wei-Fan Hsu)，附醫廠商計畫，評估單一遞增劑量與多重劑量GSK3389404使用於慢性B型肝炎受試者之安全性、耐受性、藥動學與藥效學的一項雙盲、安慰劑對照試驗，2017.1.1~2017.12.31 | 2017 . 01 |
| 21 | 臨床試驗與研究計畫，CMUH106-REC2-016，賴學洲(Lai, Hsueh-Chou)、蘇文邦(Wen-Pang Su)、王鴻偉(Hung-Wei Wang)、許偉帆(Wei-Fan Hsu)、陳昇弘(Chen, Sheng-Hung)、陳景祥，附醫廠商計畫，探討12週daclatasvir/asunaprevir合併ribavirin對C型肝炎病毒基因型1b無NS5A病毒突變株患者治療療效與安全性研究，2017.1.1~2017.12.31 | 2017 . 01 |
| 22 | 臨床試驗與研究計畫，CMUH106-REC3-101，賴學洲(Lai, Hsueh-Chou)、蘇文邦(Wen-Pang Su)、陳昇弘(Chen, Sheng-Hung)、陳浤燿(Chen, Ching-Hsiang)、許偉帆(Wei-Fan Hsu)、王鴻偉(Hung-Wei Wang)，附醫廠商計畫，針對感染慢性C型肝炎病毒(HCV)基因型1、2、4、5 或6 型且具有代償性肝硬化而未接受過治療的成人評估Glecaprevir (GLE)/Pibrentasvir (PIB)的療效與安全性的一項單組、開放性試驗，2017.1.1~2017.12.31 | 2017 . 01 |
| 23 | 臨床試驗與研究計畫，CMUH106-REC2-070，賴學洲(Lai, Hsueh-Chou)、蘇文邦(Wen-Pang Su)、陳昇弘(Chen, Sheng-Hung)、陳景祥、許偉帆(Wei-Fan Hsu)、王鴻偉(Hung-Wei Wang)，附醫廠商計畫，一項第 2 期、多中心、開放標示試驗，在患有基因型1、4、5、6 慢性C型肝炎感染且接受透析治療的末期腎病受試者中，評估Ledipasvir/Sofosbuvir 的療效及安全性，2017.1.1~2017.12.31 | 2017 . 01 |
專利技術
暫無資料獲獎事蹟
|
獲獎／Award (獲獎名稱，給獎單位，獲獎日期) |
日期 | |
| 1 | Outstanding Poster Award，台灣肝癌醫學會，2024.5.18 | 2024 . 05 |
| 2 | 2022 APASL-TOP 100 Outstanding Abstract，Asian Pacific Association for the Study of the Liver，2022.6.25 | 2022 . 06 |
